GlassScriptPhysician profile
Lolita Camp
NPI 1083782734
$10,217.57
in general payments reported to CMS, 2019-2025
35 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,128 · 2022: $2,582 · 2023: $1,837 · 2024: $1,899 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,506.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,984.38 | 2021-2025 | Epclusa, Descovy, Yeztugo |
| Teva Pharmaceuticals USA, INC. | $851.10 | 2021-2025 | Austedo Xr, Uzedy |
| Genzyme Corporation | $684.33 | 2021-2025 | |
| Abbvie INC. | $578.91 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $482.32 | 2022-2025 | Strensiq |
| Medtronic, INC. | $399.38 | 2022-2025 | Interstim |
| Astrazeneca Pharmaceuticals LP | $366.66 | 2022-2025 | Wainua, Tezspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $300.00 | 2022-2024 | Lifevest |
| Neurelis, INC. | $299.36 | 2021-2024 | Valtoco |
| Abbott Laboratories | $290.48 | 2022-2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $269.71 | 2025 | Rezdiffra |
| Dexcom, INC. | $238.75 | 2021-2023 | Dexcom G7 Gss (161) |
| Viiv Healthcare Company | $227.30 | 2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $139.67 | 2025 | |
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2024 | Jardiance |
| Amgen INC. | $124.99 | 2022 | |
| Sanofi Pasteur INC. | $124.97 | 2023 | |
| Novo Nordisk INC | $123.47 | 2022 | |
| Xeris Pharmaceuticals, INC. | $121.87 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | Dupixent |
| Idorsia Pharmaceuticals US INC | $120.39 | 2023 | Quviviq |
| Agile Therapeutics, INC. | $111.37 | 2021 | |
| Insmed, INC. | $102.35 | 2025 | Arikayce |
| Impel Pharmaceuticals INC. | $99.99 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.99 | 2024 | |
| Nevro Corp. | $98.49 | 2022 | |
| Jazz Pharmaceuticals INC. | $97.46 | 2021 | |
| Lilly USA, LLC | $95.43 | 2024 | Zepbound |
| Neurocrine Biosciences, INC. | $94.11 | 2021 | |
| Mannkind Corporation | $84.34 | 2022 | |
| Boston Scientific Corporation | $70.72 | 2021 | |
| Theratechnologies INC. | $59.80 | 2022 | |
| Shionogi INC | $51.98 | 2021 | |
| Exact Sciences Corporation | $51.68 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lolita Camp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.